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I. Abstract
Kabuki Syndrome (KS) is a rare genetic disorder characterized by multiple developmental abnormalities, and varying degrees of cognitive impairment. Hallmark features of this disorder typically include distinctive facial features, skeletal and
dermatoglyphic abnormalities, intellectual disability, and postnatal short stature. These features form the basis for diagnosis, though individuals suffering from KS will present a host of other ailments spanning from cardiovascular and digestive
abnormalities, to immunological deficiencies. The majority of cases arise due to de novo mutations, but KS can be inherited through autosomal dominance. Genes identified as suspect in the disease’s manifestation include KMT2D and KMD6A,
which are both involved in histone modification. Mutations in these genes account for 75% of those clinically diagnosed with KS. Treatment is centered around the mitigation of symptomology unique to each patient, and early diagnosis is crucial
to improving prognosis. Recent findings have shown that neurological and immunological pathology has potential for improvement in animal models, as well as the role of hypoinsulinism in the manifestation of hypotonia and growth retardation.
This presentation seeks to review recent data on KS, and to provide information on the role of development in this disease.

IV. Effects on Development in Select Organ Systems

II. Diagnosis
Diagnosis of KS can be confirmed via
genetic testing for mutations in
KMT2D or KMD6A gene mutations,
though 30% of patients with KMS do
not have a mutation in either of these
genes. Blood tests have been made
available to those who may suspect
this mutation runs in their family,
including fetal blood tests.
Patients with an unknown mutation
are diagnosed based on
symptomology, patient history, and
thorough clinical evaluation. Symptom
based diagnosis of KS involves an
individual exhibiting at least 4 of these
5 common symptoms: distinctive facial
features (fig. 4), skeletal abnormalities
(fig. 1), intellectual disability,
dermatoglyphic abnormalities such as
persistent fetal finger pads, and
postnatal short stature (fig. 2)

Symptoms such as hypotonia can often
be the result of hyperinsulinism,
which may be underdiagnosed in
patients with presenting with a
mutation in KMD6A [5].

Figure 1. Elongated halluces of
the feet in two patients with KS.
A common example of skeletal
abnormalities [11].

Figure 2.
Persistent fetal
finger pads as
found in a patient
with KS [15].

Immunological Deficiency
Mouse model studies have found that the S100A gene cluster is profoundly
suppressed in KS mutations, explaining this complexes’ important role in
cardiogenesis. Other pathways implicated in pathology include: wnt/ betacatenin, cardiac stem cell differentiation, cAMP signaling, b-cell development,
and cardiac beta-adrenergic signaling [6].
Zebrafish studies simulating KS mutations show that both proteins play a role
in early development, especially within craniofacial, brain, and cardiac
morphogenesis [14]. Haploisufficiency in either of these genes results
hypoplasia of pharyngeal arches, explaining KS craniofacial abnormalities (fig
6). Cardiac development was impaired specifically within cardiac looping
involution, resulting in septal defects, and abnormal development of the
ventricles and atria. Embryological development of the midbrain also appeared
to be altered. Examination of midbrain cells indicated neuronal precursor cells
had an impaired ability to differentiate [14].
Neurological Impairment
Patients often present mild intellectual impairment, as well as experience partial
seizures. Neurological structures do not seem grossly affected, though
hippocampal atrophy and enlargement of the ventricles have been found [2]. It is
hypothesized that seizures are the result of cerebral hyperexcitability rather than
neurological malformations. Mouse models of heterozygous KMT2D mutation
exhibited a decreased dente gyrus mass and lowered hippocampal functioning,
supporting prior findings of neurological impairment in KS. Interestingly,
researchers of this study found that inhibition of histone deacetylase could
mitigate neurological impairment during development in these models [3] .

III. Mutations
KMT2D and KMD6A both code for
methyltransferases involved in histone
modification and chromatin modeling (fig.
3), and are part of the large protein complex
ASCOM [9,10]. This complex seems to play
an important role in expressing cell
signaling intermediaries important to
development (tab. 1). Unfortunately, the
mechanisms behind these interactions are
poorly understood, though the ASCOM
complex appears to be essential in the
differential expression of many genes.

Table 1. Signaling pathways downregulated in KMT2D mutations.
Implicates ASCOM’s role in development [6].

Figure 3. Chromosomal locations of KMT2D (above) and KMD6A (below).
KMT2D codes for Histone-lysine N methyltransferase 2D
[9], and KMD6A codes for Lysine Demethylase 6A [10]..

Figure 4. Typical facial gestalt
seen in KS. Craniofacial
abnormalities include
pronounced ears, depressed nasal
tip, arched eyebrows, and
elongated palpebral fissures [7].

KS seems to generate symptoms in patients that are similar to common variable
immunodeficiency as a result of either autoimmunity, or decreased serum
antibodies. Patients often suffer from chronic upper respiratory infections, and
otitis media, which may contribute to hearing loss [13]. A case study of 14 female
patients with KMT2D mutations showed that lymphocyte proliferation did not
seem to be markedly affected, though differentiation of memory cells was
impaired. Cytokine production was also reduced (IL-2, IL-12, IFN gamma), as
well as serum Ab IgG, IgG2, and IgA. CD molecules also appeared to be reduced
[12]. Patients treated with supplemental antibodies seemed to have reduced
occurrence of bacterial infection [12].
Cardiac Abnormalities
Congenital heart defects are found in roughly 40-50% of patients with KS, and
are not limited to either of the two mutations. Frequently found malformations
are atrial septal defects, ventricular septal defects and aortic coarctation [4].
Surgical intervention is sometimes required to mitigate these defects. KMT2D
haploinsufficient mouse models show a general narrowing of the ascending
aorta. Those with a complete KMT2D knockout exhibit decreased cardiomyocyte
proliferation and inviability, implicating this gene’s role in cardiac formation
during development [1].

Figure 5. Comparison of
embryological
pharyngeal crests in WT
and knockout zebrafish
[14].
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